Multi center study supports Castle Biosciences DecisionDx SCC test accuracy

Multi center study supports Castle Biosciences DecisionDx SCC test accuracy
Castle Biosciences validates SCC test

Castle Biosciences announced the publication of a multi-center study in the Journal of the American Academy of Dermatology validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma.

The study involved multiple centers and provides peer-reviewed evidence supporting the clinical use of the DecisionDx-SCC test for improving risk classification in these patients.

Castle Biosciences has recently outlined new strategies in advanced diagnostics and data innovation at the Future Biotech Expo 2026. The company also began dual listing on Nasdaq Texas while maintaining its primary listing on the Nasdaq Global Market under the ticker CSTL, according to a recent announcement. These developments reflect Castle Biosciences' ongoing efforts to expand its product offerings and market presence.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.